Case 1
A 40-year-old female patient underwent a segmentectomy because of an inhomogeneous hepatic mass. Macroscopic examination showed a solid 90-mm lesion with light and dark brown areas and some small (1-14 mm) whitish nodules (Fig. 1A) . Microscopic examination showed a hepatocellular proliferation without atypical features at the background (Fig. 1B,C) . Glutamine synthetase (GS) appreciated a faint heterogeneous expression at the center and a reinforcement at the periphery, a surrogate pattern of β-catenin activation. C-reactive protein (CRP) staining was negative ( Fig. 1D ). The sections corresponding to the whitish nodules revealed decreased and disorganized reticulin network and positivity for glypican-3 ( Fig.  1E ), features pointing toward HCC transformation with good differentiation. Additional molecular analysis of the main lesion confirmed exon 7 mutation in CTNNB1 (B ex7 HCA) and telomerase reverse-transcriptase (TERT) promoter mutation in the areas with HCC transformation.
In a benchmark study from 2017, <4% of included patients with HCA had B ex7 HCA, and malignant transformation was observed in none of the patients with B ex7,8 HCA. (2) The present case shows that although the risk of malignant transformation in B ex7 HCA is lower compared with B ex3 HCA, it should not be neglected.
Both had alternating pale areas with dark red foci. Microscopic examination showed features of I-HCA with sinusoidal dilatation and inflammatory infiltrates in the pseudoportal areas ( Fig. 2A-II,B -II). Immunohistochemistry demonstrated a dense and diffuse staining for CRP ( Fig. 2A-III 
Moreover, in the small nodule, a diffuse staining was found for GS with a more intense staining at the periphery of the lesion, suggesting β-catenin activation ( Fig. 2A-IV ) . Molecular analysis of the small nodule confirmed CTNNB1 mutation in exon 3. The large nodule was negative for CTNNB1 mutation. Guidelines on benign liver tumors advise to base management decisions in patients with multiple HCA on the largest lesion. (5) The aforementioned benchmark article describes intertumor heterogeneity with at least one B ex3 (I)HCA in 9 patients with multiple HCA. (2) Only 1 patient was described in whom the largest was an H-HCA and a smaller B ex3 HCA; in the remaining patients, the largest tumor had the CTNNB1 mutation.
In conclusion, these cases illustrate the existent risk of malignant transformation in B ex7/8 HCA. Pending defined indications for molecular analysis, we would propose performing mutational examination in all cases with inconclusive/equivocal immunohistochemistry, at least on biopsy material. Prospectively, this will lead to data collection and better understanding of the oncogenic β-catenin exon 7/8 and TERT mutations. Secondly, in the management of multiple HCA, the final decision should be made based on pathomolecular subclassification along with the diameter.
